Blinklab Limited
ASX: BB1
BlinkLab rises on AI diagnostics progress and healthy cash.
(Source: TradingView) 3-Month Performance Profile of BB1 on a DTF compared to S&P/ASX 200 (XJO).
For the half-year ended 31 December 2024, BlinkLab Limited saw a notable rise in revenue, largely fueled by ongoing clinical trials and advancements in product development. The company’s AI and machine learni
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
